drugset / Trial / NCT04070742

Dermal Phototoxicity Study

NCT04070742 ↗

Phase 1 Completed 32 enrolled Vyne Therapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

Dermal Safety study to determine the Phototoxicity Potential of FMX-101 4% in Healthy Volunteers

Timeline

Start
2016-08-17
Primary completion
2016-09-07
Completion
2016-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject FMX-101 Unknown 4 % —

Indications

No indication recorded.